GenesisCare and PreludeDx™ Form Precision Medicine Global Partnership apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
Cancer Patients in Asheville Benefit from Major Boost to GenesisCare Surgical Oncology Program
Five highly regarded surgical Oncologists join Comprehensive Cancer Treatment Center Utilizing Artificial Intelligence and Robotics
News provided by
Share this article
ASHEVILLE, N.C., April 29, 2021 /PRNewswire/
GenesisCare one of the leading oncology providers in the United States, Australia, Spain, and the United Kingdom today announced the addition of five well-respected surgeons to the Asheville team of GenesisCare USA of North Carolina, PA. GenesisCare Surgical Specialists will be working to put into practice more than 20 life-saving surgical procedures providing comprehensive cancer care across medical and radiation oncology. The collection of comprehensive procedures and surgeons allows the facility to offer treatments for breast, colon, pancreatic, thyroid, skin, and other metastatic cancers.
GenesisCare and PreludeDx™ Partner to Provide Access to Ground-Breaking Precision Medicine Test for Women With Early-Stage Breast Cancer
on February 23 2021 9:00 PM
SYDNEY & LAGUNA HILLS, Calif. (BUSINESS WIRE) #breastcancerawareness GenesisCare, a leading provider of integrated cancer care globally, and Prelude Corporation (PreludeDx
TM), a leader in molecular diagnostics and precision medicine, today announced a new strategic partnership aimed at increasing access to personalized breast cancer treatment and improved patient outcomes.
DCISionRT
® is a precision medicine test for women diagnosed with DCIS (Ductal Carcinoma in situ) or Stage 0 breast cancer who are treated with breast-conserving surgery. The DCISionRT test, developed by PreludeDx, assesses a woman’s 10-year risk of recurrence of DCIS or development of invasive breast cancer. The test provides predictive information regarding recurrence risk, allowing physicians to better select those patients who will benefi
GenesisCare Brings Western North Carolina Cancer Patients Elekta Versa HD™ Technology
New Linear Radiotherapy Shortens Brain, Lung, and Metastases Treatment Time With Better Results, While Reducing Damage to Healthy Tissue
News provided by
Share this article
ASHEVILLE, N.C., Feb. 18, 2021 /PRNewswire/
GenesisCare one of the leading oncology providers in the United States, Australia, Spain, and the United Kingdom today announced the addition of the new Elekta Versa HD™ at its Asheville location. This innovative technology is available to oncology patients with brain, lung, and metastases cancer throughout Western North Carolina and nearby areas. With shorter treatment times, this hypofractionated radiation therapy provides the highest level of dose delivery accuracy while pushing the boundaries of stereotactic capabilities that can be delivered in a standard therapy slot of 15 minutes or less, which was not previously possible.